GP+PD-1+Tight

DRUG2 trials

Sponsors

Fudan University, Shanghai Zhongshan Hospital

Conditions

Biliary Tract CarcinomaIntrahepatic Cholangiocarcinoma

Phase 2

GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

WithdrawnNCT05019677

Fudan UniversityIntrahepatic Cholangiocarcinoma

Start: 2021-09-01End: 2024-12-01Updated: 2022-04-04

GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC

Shanghai Zhongshan HospitalBiliary Tract Carcinoma

Start: 2021-02-01End: 2024-12-01Target: 45Updated: 2023-08-15

Related Papers

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.

2025-08-212 citations

ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).

Journal of Clinical Oncology2024-01-204 citations